{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:59:18Z","timestamp":1785135558045,"version":"3.55.0"},"reference-count":18,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The COVID-19 pandemic substantially disrupted healthcare systems worldwide, raising concerns regarding delays in diagnosis, alterations in treatment pathways, and oncological outcomes for women with advanced ovarian cancer (AOC). This study evaluated the impact of the pandemic on the management and survival of patients with AOC treated at a high-volume ESGO-accredited tertiary gynaecological oncology centre. Methods: A retrospective cohort study was conducted using a prospectively maintained database of consecutive women diagnosed with FIGO stage III\u2013IV epithelial ovarian, fallopian tube or primary peritoneal cancer between January 2017 and December 2022. Patients were divided into pre-pandemic and pandemic cohorts. Demographic characteristics, FIGO stage, treatment pathways, surgical outcomes, and overall survival were compared. Survival was analysed using Kaplan\u2013Meier methodology and multivariable Cox proportional hazards regression was performed to evaluate the independent association between the pandemic period and overall survival after adjustment for age, FIGO stage, ECOG performance status and treatment modality. Results: A total of 700 patients were included, 406 patients treated before the pandemic and 294 during the pandemic. Patients diagnosed during the pandemic had a better ECOG performance status, but 51.3% presented with FIGO stage IV disease. Overall treatment rates were maintained (84.4% vs. 87.4% pre-pandemic), although treatment strategies shifted towards increased use of neoadjuvant chemotherapy (55% vs. 42.4%, p &lt; 001), with a greater proportion of patients subsequently undergoing interval debulking surgery. Complete cytoreduction following interval debulking surgery was preserved throughout the study period, despite more advanced disease at presentation. One-year overall survival was similar between cohorts (69% vs. 72.2% pre-pandemic), whereas three-year overall survival was significantly lower among patients treated during the pandemic (36.1% vs. 45.1%). On multivariable Cox regression analysis, treatment during the pandemic remained independently associated with poorer overall survival after adjustment for clinically relevant baseline factors. Conclusions: Despite unprecedented disruption to healthcare services, specialist gynaecological oncology care has maintained access to multimodality treatment and preserved maximal effort cytoreductive surgery. Nevertheless, patients diagnosed during the pandemic experienced inferior long-term survival independent of baseline disease characteristics and treatment allocation, highlighting the broader indirect consequences of the pandemic on cancer outcomes. These findings emphasise the importance of protecting diagnostic pathways, multidisciplinary cancer services and surgical capacity during future healthcare crises.<\/jats:p>","DOI":"10.3390\/cancers18152403","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:49:27Z","timestamp":1785131367000},"page":"2403","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maximal Cytoreductive Effort in the Time of Pandemic: Outcomes for Patients with Advanced Ovarian Cancer and Lessons for the Future"],"prefix":"10.3390","volume":"18","author":[{"given":"Porfyrios","family":"Korompelis","sequence":"first","affiliation":[{"name":"NGOC, Gateshead NHS Foundation Trust, Gateshead NE9 6SX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0378-1020","authenticated-orcid":false,"given":"Anke","family":"Smits","sequence":"additional","affiliation":[{"name":"BHGOC, Barts Health NHS Trust, London E1 1FR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljinder","family":"Mann","sequence":"additional","affiliation":[{"name":"Country Durham & Darlington NHS Foundation Trust, Darlington DL3 6HX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Betts","sequence":"additional","affiliation":[{"name":"Medical School, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7202-4493","authenticated-orcid":false,"given":"Viktor","family":"Cassar","sequence":"additional","affiliation":[{"name":"Mater Dei Hospital, MSD 2090 Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7713-3202","authenticated-orcid":false,"given":"V. B. Swetha","family":"Rongali","sequence":"additional","affiliation":[{"name":"Sandwell & West Birmingham NHS Trust, West Bromwich B71 4HJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5903-6285","authenticated-orcid":false,"given":"Christine","family":"Ang","sequence":"additional","affiliation":[{"name":"NGOC, Gateshead NHS Foundation Trust, Gateshead NE9 6SX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-3723","authenticated-orcid":false,"given":"Dominic","family":"Blake","sequence":"additional","affiliation":[{"name":"NGOC, Gateshead NHS Foundation Trust, Gateshead NE9 6SX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-3347","authenticated-orcid":false,"given":"Stuart","family":"Rundle","sequence":"additional","affiliation":[{"name":"NGOC, Gateshead NHS Foundation Trust, Gateshead NE9 6SX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","unstructured":"GOV.UK (2025, March 01). Coronavirus (COVID-19) in the UK, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/articles\/coronaviruscovid19latestinsights\/deaths."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jso.27048","article-title":"Treatment delay and treatment pattern modifications among epithelial ovarian cancer patients during the COVID-19 pandemic: A retrospective cohort study","volume":"126","author":"Moterani","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/bjs.11728","article-title":"COVID-19 pandemic impact on gynaecological cancers: A perspective","volume":"107","author":"Uwins","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/CCI.20.00134","article-title":"Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors","volume":"4","author":"Patt","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_5","first-page":"1440","article-title":"Elective surgery cancellations due to the COVID-19 pandemic: Global predictive modelling to inform surgical recovery plans","volume":"107","author":"Nepogodiev","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejogrb.2017.04.016","article-title":"British Gynaecological Cancer Society (BGCS) epithelial ovarian\/fallopian tube\/primary peritoneal cancer guidelines: Recommendations for practice","volume":"213","author":"Fotopoulou","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_8","unstructured":"Target Ovarian Cancer (2025, March 01). Voices of Women with Ovarian Cancer: The Coronavirus Pandemic and Its Impact. Available online: https:\/\/targetovariancancer.org.uk\/sites\/default\/files\/2020-07\/Voices%20of%20women%20with%20ovarian%20cancer%20-%20the%20coronavirus%20pandemic%20and%20its%20impact.pdf."},{"key":"ref_9","unstructured":"NIHR (2025, March 01). Global Health Research, COVID-Surg Collaboration. Available online: https:\/\/globalsurg.org\/covidsurg\/."},{"key":"ref_10","unstructured":"(2025, March 01). COVID-19 Genomics UK (COG-UK) Consortium. Available online: https:\/\/www.sanger.ac.uk\/collaboration\/covid-19-genomics-uk-cog-uk-consortium\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CMAR.S287152","article-title":"Impact of COVID-19 Pandemic on Ovarian Cancer Management: Adjusting to the New Normal","volume":"13","author":"Jacome","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_12","unstructured":"(2025, March 01). OCAFP. Available online: https:\/\/digital.nhs.uk\/ndrs\/our-work\/ncras-partnerships\/ovarian-cancer-feasibility-pilot."},{"key":"ref_13","unstructured":"BA-SO-The Association for Cancer Surgery (2020). BASO Guidance\u2014Strategy for Cancer Surgery Sustainability and Recovery in the COVID 19 Pandemic, BA-SO-The Association for Cancer Surgery."},{"key":"ref_14","first-page":"iv1","article-title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Morice","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","article-title":"The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: A national, population-based, modelling study","volume":"21","author":"Maringe","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","unstructured":"(2025, March 01). World Health Organization. Available online: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report.pdf."},{"key":"ref_17","unstructured":"NHS England (2025, March 01). Cancer Waiting Times Review. Available online: https:\/\/www.england.nhs.uk\/long-read\/cancer-waiting-times-review."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-021-01588-6","article-title":"The \u201ccollateral damage\u201d of the war on COVID-19: Impact of the pandemic on the care of ep-ithelial ovarian cancer","volume":"38","author":"Goenka","year":"2021","journal-title":"Med. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2403\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:03:47Z","timestamp":1785132227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":18,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152403"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152403","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}